KR20220059479A - 트로피네타이드의 조성물 - Google Patents

트로피네타이드의 조성물 Download PDF

Info

Publication number
KR20220059479A
KR20220059479A KR1020227006982A KR20227006982A KR20220059479A KR 20220059479 A KR20220059479 A KR 20220059479A KR 1020227006982 A KR1020227006982 A KR 1020227006982A KR 20227006982 A KR20227006982 A KR 20227006982A KR 20220059479 A KR20220059479 A KR 20220059479A
Authority
KR
South Korea
Prior art keywords
formula
compound
weight
hydrate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227006982A
Other languages
English (en)
Korean (ko)
Inventor
클라이브 블라워
매튜 피터슨
제임스 머레이 쇼
제임스 안토니 보나르
에티엔 데이비드 프랭크 필립 모니오트
마틴 버나드 캐서린 부즈만
세실리아 베티
카렐 윌리 루크 데크루즈
미모운 아우브
Original Assignee
뉴렌 파마슈티컬즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴렌 파마슈티컬즈 리미티드 filed Critical 뉴렌 파마슈티컬즈 리미티드
Publication of KR20220059479A publication Critical patent/KR20220059479A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/06—Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/18—Carbon
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Materials Engineering (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227006982A 2019-08-05 2020-08-03 트로피네타이드의 조성물 Pending KR20220059479A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882998P 2019-08-05 2019-08-05
US62/882,998 2019-08-05
PCT/US2020/044733 WO2021026066A1 (en) 2019-08-05 2020-08-03 Compositions of trofinetide

Publications (1)

Publication Number Publication Date
KR20220059479A true KR20220059479A (ko) 2022-05-10

Family

ID=74502416

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227006982A Pending KR20220059479A (ko) 2019-08-05 2020-08-03 트로피네타이드의 조성물

Country Status (16)

Country Link
US (3) US11370755B2 (https=)
EP (1) EP4009962A4 (https=)
JP (2) JP2022543391A (https=)
KR (1) KR20220059479A (https=)
CN (1) CN114667136A (https=)
AU (1) AU2020324396B2 (https=)
BR (1) BR112022002229A2 (https=)
CA (1) CA3149633A1 (https=)
CL (1) CL2022000301A1 (https=)
CO (1) CO2022002616A2 (https=)
IL (1) IL290324A (https=)
JO (1) JOP20220027A1 (https=)
MX (1) MX2022001505A (https=)
MY (1) MY206115A (https=)
SA (1) SA522431585B1 (https=)
WO (1) WO2021026066A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220059479A (ko) 2019-08-05 2022-05-10 뉴렌 파마슈티컬즈 리미티드 트로피네타이드의 조성물
MX2023014655A (es) * 2021-07-12 2024-01-12 Acadia Pharm Inc Formas cristalinas de trofinetida.
WO2025169163A1 (en) * 2024-02-10 2025-08-14 Teadus Pharma Private Limited Method for the synthesis of trofinetide and its analogues

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2573765B1 (fr) * 1984-11-23 1988-06-10 Solvay Procede pour la synthese de peptides
US8637567B2 (en) 2001-05-24 2014-01-28 Neuren Pharmaceuticals Ltd. Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
ATE435852T1 (de) 2001-05-24 2009-07-15 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7863304B2 (en) 2001-05-24 2011-01-04 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
EP1888618A4 (en) * 2005-05-23 2009-07-15 Neuren Pharmaceuticals Ltd Analogs of glycyl-prolyl-glutamate
WO2007106555A2 (en) 2006-03-14 2007-09-20 Neuren Pharmaceuticals Limited Oral formulations of glycyl-2-methylprolyl-glutamate
EP2060580A1 (en) * 2007-11-19 2009-05-20 SOLVAY (Société Anonyme) Process for the manufacture of persilylated peptides
AU2012209466C1 (en) * 2011-01-27 2016-06-23 Neuren Pharmaceuticals Limited Treatment of Autism Spectrum Disorders using Glycyl-L-2-Methylprolyl-L-Glutamic Acid
US20150224164A1 (en) * 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
KR20220059479A (ko) 2019-08-05 2022-05-10 뉴렌 파마슈티컬즈 리미티드 트로피네타이드의 조성물

Also Published As

Publication number Publication date
MY206115A (en) 2024-11-29
US12297172B2 (en) 2025-05-13
CA3149633A1 (en) 2021-02-11
EP4009962A1 (en) 2022-06-15
JP2022543391A (ja) 2022-10-12
US11866406B2 (en) 2024-01-09
MX2022001505A (es) 2022-03-11
US20240109841A1 (en) 2024-04-04
EP4009962A4 (en) 2023-08-09
CO2022002616A2 (es) 2022-06-10
US20220324799A1 (en) 2022-10-13
CL2022000301A1 (es) 2022-09-20
JP2026063085A (ja) 2026-04-10
BR112022002229A2 (pt) 2022-04-19
SA522431585B1 (ar) 2025-02-13
AU2020324396B2 (en) 2025-07-03
US20220055987A1 (en) 2022-02-24
AU2020324396A1 (en) 2022-03-10
IL290324A (en) 2022-04-01
JOP20220027A1 (ar) 2023-01-30
CN114667136A (zh) 2022-06-24
US11370755B2 (en) 2022-06-28
WO2021026066A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
JP5789260B2 (ja) Ｃ型肝炎ウイルスのプロテアーゼ阻害薬の調製方法
CN101663294A (zh) Hcv蛋白酶抑制剂中间体的制备方法
JP2026063085A (ja) トロフィネチドの組成物
AU2022428318A1 (en) Method for producing n-alkyl amino acid and peptide including n-alkyl amino acid
ES2715082T3 (es) Método de producción de un pentapéptido sintético
CN108727468B (zh) 环肽、包含其的医药或化妆品组成物及其制备方法
EP3924330A1 (en) Method of preparing a don prodrug from l-glutamic acid
JP2026016830A (ja) 合成プロセス及び中間体
CN115190882A (zh) 通过共同中间体有效制备多拉司他汀和奥里斯他汀类似物
WO2020262259A1 (ja) ペプチド化合物の製造方法、保護基形成用試薬、及び、縮合多環化合物
CN120476131A (zh) 涉及位阻三叔丁基色氨酸（Tbt）残基的肽合成方法
WO2024075813A1 (ja) ジケトピペラジン化合物を用いるポリペプチド合成
JP5807140B1 (ja) 合成ペンタペプチドの製造法
WO2023275410A1 (en) Peptide synthesis method involving sterically hindered mixed anhydride intermediate
US20040101864A1 (en) Chemical process
KR20160120345A (ko) H-inp-(d)bal-(d)trp-phe-apc-nh2의 액체상 합성을 위한 공정, 및 이들의 약학적으로 허용 가능한 염들
EA049473B1 (ru) Композиции трофинетида
US9751911B2 (en) Solomonamide analogue compounds, pharmaceuticals containing solomonamide analogue compounds, and processes for the preparation thereof
JP5982720B2 (ja) 高分子固体状支持体を用いたヒスチジル−プロリンアミド誘導体の製造方法
HUP0003788A2 (hu) Aza-cikloalkil-alkanoil-pszeudotetrapeptidek, intermedierjeik és előállításukra szolgáló eljárások
HK40096738A (zh) 包含n-取代氨基酸残基的环状化合物的制备方法
KR20110073473A (ko) 펩티드 화합물 및 그의 제조 방법
KR20190043031A (ko) 아마톡신 유도체 및 이의 제조방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000